Glassman Wealth Services Mirati Therapeutics, Inc. Transaction History

Glassman Wealth Services

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$41.99 - $62.38 $3,737 - $5,551	89 New	89 $5,000
Q2 2023 Aug 08, 2023	SELL	$36.13 - $49.49 $3,143 - $4,305	-87 Reduced 93.55%	6 $0
Q1 2023 May 04, 2023	BUY	$36.54 - $54.26 $3,105 - $4,612	85 Added 1062.5%	93 $3,000
Q4 2022 Feb 06, 2023	SELL	$41.27 - $98.62 $82 - $197	-2 Reduced 20.0%	8 $0
Q2 2022 Aug 04, 2022	SELL	$39.16 - $88.71 $5,012 - $11,354	-128 Reduced 92.75%	10 $1,000

Q1 2022 Aug 23, 2022	BUY	$75.82 - $150.97 $227 - $452	3 Added 2.22%	138 $11,000
Q1 2022 Apr 14, 2022	BUY	$75.82 - $150.97 $10,084 - $20,079	133 Added 6650.0%	135 $11,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $6,864 - $9,895	-52 Reduced 96.3%	2 $0
Q3 2021 Nov 10, 2021	BUY	$132.13 - $177.45 $7,135 - $9,582	54 New	54 $10,000
Q3 2019 Nov 01, 2019	SELL	$77.91 - $109.6 $233 - $328	-3 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$59.49 - $104.71 $178 - $314	3 New	3 $0

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.